Abstract
Advances in our understanding of autoimmunity and tumour immunity have led to improvements in immunotherapy for these diseases. Ironically, effective tumour immunity requires the induction of the same responses that underlie autoimmunity, whereas autoimmunity is driven by dysregulation of the same mechanisms that are involved in host defence and immune surveillance. Therefore, as we manipulate the immune system to treat cancer or autoimmunity, we inevitably unbalance the vital mechanisms that regulate self tolerance and antimicrobial resistance. This Science and Society article aims to dissect the conundrum that is inherent to the concept of immunotherapy and highlights the need for new and more specific therapeutic approaches.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Leveraging structural and 2D-QSAR to investigate the role of functional group substitutions, conserved surface residues and desolvation in triggering the small molecule-induced dimerization of hPD-L1
BMC Chemistry Open Access 27 June 2022
-
Durable tracking anti-SARS-CoV-2 antibodies in cancer patients recovered from COVID-19
Scientific Reports Open Access 30 August 2021
-
The possible puzzles of BCG vaccine in protection against COVID-19 infection
The Egyptian Journal of Bronchology Open Access 27 January 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Good, R. A. Relations between immunity and malignancy. Proc. Natl Acad. Sci. USA 69, 1026–1032 (1972).
Busnach, G. et al. Immunosuppression and cancer: a comparison of risks in recipients of organ transplants and in HIV-positive individuals. Transplant Proc. 38, 3533–3535 (2006).
Bongartz, T. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275–2285 (2006).
Chatenoud, L. Immune therapies of autoimmune diseases: are we approaching a real cure? Curr. Opin. Immunol. 18, 710–717 (2006).
Scott, C. T. The problem with potency. Nature Biotechnol. 23, 1037–1039 (2005).
Marmont, A. M. Will hematopoietic stem cell transplantation cure human autoimmune diseases? J. Autoimmun. 30, 145–150 (2008).
Waldmann, T. A. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J. Clin. Immunol. 27, 1–18 (2007).
Miller, S. D., Turley, D. M. & Podojil, J. R. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nature Rev. Immunol. 7, 665–677 (2007).
Feldmann, M. & Steinman, L. Design of effective immunotherapy for human autoimmunity. Nature 435, 612–619 (2005).
Passweg, J. & Tyndall, A. Autologous stem cell transplantation in autoimmune diseases. Semin. Hematol. 44, 278–285 (2007).
Leen, A. M., Rooney, C. M. & Foster, A. E. Improving T cell therapy for cancer. Annu. Rev. Immunol. 25, 243–265 (2007).
Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A. & Dudley, M. E. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nature Rev. Cancer 8, 299–308 (2008).
Gogas, H. et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354, 709–718 (2006).
Parmiani, G., Rivoltini, L., Andreola, G. & Carrabba, M. Cytokines in cancer therapy. Immunol. Lett. 74, 41–44 (2000).
Adams, G. P. & Weiner, L. M. Monoclonal antibody therapy of cancer. Nature Biotechnol. 23, 1147–1157 (2005).
Ozcelik, C. et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl Acad. Sci. USA 99, 8880–8885 (2002).
Silk, A. W. & Finn, O. J. Cancer vaccines: a promising cancer therapy against all odds. Future Oncol. 3, 299–306 (2007).
Arlen, P. M., Gulley, J. L., Madan, R. A., Hodge, J. W. & Schlom, J. Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. Crit. Rev. Immunol. 27, 451–462 (2007).
Hodi, F. S. et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc. Natl Acad. Sci. USA 105, 3005–3010 (2008).
Dudley, M. E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850–854 (2002).
Dudley, M. E. et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23, 2346–2357 (2005).
Sugita, S. et al. Ocular infiltrating CD4+ T cells from patients with Vogt–Koyanagi–Harada disease recognize human melanocyte antigens. Invest. Ophthalmol. Vis. Sci. 47, 2547–2554 (2006).
Norose, K. & Yano, A. Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt–Koyanagi–Harada disease. Br. J. Ophthalmol. 80, 1002–1008 (1996).
Maker, A. V. et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann. Surg. Oncol. 12, 1005–1016 (2005).
Robinson, M. R. et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J. Immunother. 27, 478–479 (2004).
Beck, K. E. et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 24, 2283–2289 (2006).
Attia, P. et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23, 6043–6053 (2005).
Small, E. J. et al. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 13, 1810–1815 (2007).
Towns, K., Bedard, P. L. & Verma, S. Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer. Curr. Oncol. 15, S16–S29 (2008).
Lindstrom, J. M. Acetylcholine receptors and myasthenia. Muscle Nerve 23, 453–477 (2000).
Nagy, E. V. et al. Thyrotropin receptor T cell epitopes in autoimmune thyroid disease. Clin. Immunol. Immunopathol. 75, 117–124 (1995).
Amagai, M. Autoimmunity against desmosomal cadherins in pemphigus. J. Dermatol. Sci. 20, 92–102 (1999).
Roep, B. O. T-cell responses to autoantigens in IDDM. The search for the Holy Grail. Diabetes 45, 1147–1156 (1996).
Steinman, L. Antigen-specific therapy of multiple sclerosis: the long-sought magic bullet. Neurotherapeutics 4, 661–665 (2007).
Yamamoto, J. H., Minami, M., Inaba, G., Masuda, K. & Mochizuki, M. Cellular autoimmunity to retinal specific antigens in patients with Behcet's disease. Br. J. Ophthalmol. 77, 584–589 (1993).
Tripathi, P., Saxena, S., Yadav, V. S., Naik, S. & Singh, V. K. Human S-antigen: peptide determinant recognition in uveitis patients. Exp. Mol. Pathol. 76, 122–128 (2004).
Kawakami, Y. et al. T cell immune responses against melanoma and melanocytes in cancer and autoimmunity. Pigment Cell Res. 13 (Suppl. 8), 163–169 (2000).
Kappos, L. et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nature Med. 6, 1176–1182 (2000).
Bielekova, B. et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nature Med. 6, 1167–1175 (2000).
Weber, M. S., Hohlfeld, R. & Zamvil, S. S. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics 4, 647–653 (2007).
Freedman, M. S. et al. Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison. Eur. Neurol. 60, 1–11 (2008).
Feldmann, M. Development of anti-TNF therapy for rheumatoid arthritis. Nature Rev. Immunol. 2, 364–371 (2002).
[No authors listed]. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 53, 457–465 (1999).
Lin, J. et al. TNFα blockade in human diseases: an overview of efficacy and safety. Clin. Immunol. 126, 13–30 (2008).
De Bandt, M. Lessons for lupus from tumour necrosis factor blockade. Lupus 15, 762–767 (2006).
Kassiotis, G. & Kollias, G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J. Exp. Med. 193, 427–434 (2001).
Hauser, S. L. et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358, 676–688 (2008).
Herold, K. C. et al. A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54, 1763–1769 (2005).
Chatenoud, L. & Bluestone, J. A. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nature Rev. Immunol. 7, 622–632 (2007).
Rose, J. W., Foley, J. & Carlson, N. Monoclonal antibody treatments for multiple sclerosis. Curr. Neurol. Neurosci. Rep. 8, 419–426 (2008).
Nussenblatt, R. B. et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc. Natl Acad. Sci. USA 96, 7462–7466 (1999).
Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Regulatory T cells and immune tolerance. Cell 133, 775–787 (2008).
Zerhouni, E. A., Sanders, C. A. & von Eschenbach, A. C. The Biomarkers Consortium: public and private sectors working in partnership to improve the public health. Oncologist 12, 250–252 (2007).
Vincenti, F. Costimulation blockade in autoimmunity and transplantation. J. Allergy Clin. Immunol. 121, 299–306 (2008).
Breedveld, F. C. et al. Infliximab in active early rheumatoid arthritis. Ann. Rheum. Dis. 63, 149–155 (2004).
Wei, M. Q., Mengesha, A., Good, D. & Anne, J. Bacterial targeted tumour therapy — dawn of a new era. Cancer Lett. 259, 16–27 (2008).
Adorini, L. Cytokine-based immunointervention in the treatment of autoimmune diseases. Clin. Exp. Immunol. 132, 185–192 (2003).
Browning, J. L. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nature Rev. Drug Discov. 5, 564–576 (2006).
Suntharalingam, G. et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018–1028 (2006).
Acknowledgements
The author's work is funded by the National Institutes of Health Intramural Program.
Author information
Authors and Affiliations
Related links
Related links
DATABASES
OMIM
FURTHER INFORMATION
Glossary
- Altered peptide ligand
-
(APL). A peptide analogue in which the key T-cell receptor contact residues are altered, leading to the induction of only a partial response by the T cells that are specific for the original agonist peptide. Some APLs may stimulate regulatory T cells without activating effector T cells.
- Crohn's disease
-
A form of chronic inflammatory bowel disease that can affect the entire gastrointestinal tract, but is most common in the colon and terminal ileum. It is characterized by transmural inflammation, narrowing of the gut lumen and granuloma formation, and is thought to result from an abnormal T-cell-mediated immune response to commensal bacteria.
- Epitope spreading
-
The de novo activation of autoreactive T cells by self antigens that have been released after B- or T-cell-mediated bystander damage.
- Psoriasis
-
A chronic skin disease that affects 1–2% of the population, in which the skin becomes inflamed, producing red, thickened areas with silvery scales, most often on the scalp, elbows, knees and lower back. Recent evidence points to a T-cell-mediated pathogenesis in genetically susceptible individuals, which results in inflammation and epidermal hyperplasia.
- Spondyloarthropathy
-
A group of inflammatory joint diseases that are associated with the MHC class I molecule HLA-B27. It is often associated with anterior uveitis.
- Sympathetic ophthalmia
-
Destructive uveitis in one eye (sympathizing) following a penetrating wound to the other. It is considered to be an autoimmune response to antigens that are released from the wounded eye.
- Vitiligo
-
A depigmenting disorder of the skin and hair that is caused by the destruction of melanocytes that produce cutaneous pigments.
- Vogt–Koyanagi–Harada disease
-
A serious and potentially blinding condition that also targets the melanin in the anterior and the posterior pole of the eye.
Rights and permissions
About this article
Cite this article
Caspi, R. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol 8, 970–976 (2008). https://doi.org/10.1038/nri2438
Issue Date:
DOI: https://doi.org/10.1038/nri2438
This article is cited by
-
Leveraging structural and 2D-QSAR to investigate the role of functional group substitutions, conserved surface residues and desolvation in triggering the small molecule-induced dimerization of hPD-L1
BMC Chemistry (2022)
-
Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity
Nature Biomedical Engineering (2022)
-
The possible puzzles of BCG vaccine in protection against COVID-19 infection
The Egyptian Journal of Bronchology (2021)
-
Durable tracking anti-SARS-CoV-2 antibodies in cancer patients recovered from COVID-19
Scientific Reports (2021)
-
Evidence-Based Immunotherapeutic Effects of Herbal Compounds on Humoral Immunity: Ancient and New Approaches
Chinese Journal of Integrative Medicine (2021)